Amedisys (AMED) Tops Q4 EPS by 18c; Issues FY23 Guidance

Amedisys (NASDAQ: AMED) reported Q4 EPS of $1.16, $0.18 better than the analyst estimate of $0.98. Revenue for the quarter came in at $562 million versus the consensus estimate of $560.59 million.

GUIDANCE:

Amedisys sees FY2023 EPS of $4.13-$4.36, versus the consensus of $4.86. Amedisys sees FY2023 revenue of $2.244-2.274 billion, versus the consensus of $2.36 billion.

For earnings history and earnings-related data on Amedisys (AMED) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'
• Investing.com’s stocks of the week